Welcome to our dedicated page for Organogenesis Hldgs SEC filings (Ticker: ORGO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Organogenesis Holdings Inc.'s SEC filings document a regenerative medicine issuer with Class A common stock listed on the Nasdaq Capital Market. The filings cover operating and financial results for Advanced Wound Care and Surgical & Sports Medicine products, including furnished 8-K earnings releases that separate product revenue by market category.
The company's regulatory record also includes proxy materials for annual meeting matters, director elections, advisory voting items, board governance and compensation disclosures. Other filings address Regulation FD and material-event updates for ReNu clinical and regulatory matters, capital-structure details involving Class A common stock and Series A Convertible Preferred Stock voting mechanics, and risk and governance topics tied to its product portfolio.
Organogenesis Holdings Inc. vice president of health policy Antonio S. Montecalvo reported four tax-withholding dispositions of Class A Common Stock on February 15, 2026. A total of 18,619 shares were delivered at $3.73 per share to cover tax obligations, leaving him with 178,061 directly owned shares.
Organogenesis Holdings Inc. received an amended Schedule 13G from institutional investor First Light Asset Management, LLC and its control person, Mathew P. Arens, reporting their current ownership in the company’s common stock.
The filing shows First Light Asset Management may be deemed to beneficially own 3,611,616 shares, representing 2.85% of Organogenesis’ common stock. Mathew P. Arens may be deemed to beneficially own 3,888,816 shares, or 3.06% of the class, including 231,000 shares he holds directly and additional shares through joint and advised accounts.
The reporting persons certify the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Organogenesis. Because each now reports ownership below 5% of the outstanding shares, the filing confirms they are no longer large (5%+) shareholders.
Organogenesis Holdings Inc. has a large shareholder group led by Soleus Capital reporting a significant passive stake. Through Soleus Capital Master Fund, L.P., the group beneficially owns 9,985,951 shares of common stock, representing 7.9% of the outstanding shares based on 126,912,142 shares outstanding as of October 30, 2025.
All reported shares are held directly by the Master Fund, with several Soleus-affiliated entities and Guy Levy listed because of their control roles. These parties expressly disclaim beneficial ownership outside their reporting obligations under U.S. securities law and certify the holdings were not acquired to change or influence control of Organogenesis.
Organogenesis Holdings Inc. reported an insider stock transaction by a company director. On 12/16/2025, the director sold 200,000 shares of Class A Common Stock in open-market trades at a weighted-average price of $5.1353 per share, with individual trade prices ranging from $5.10 to $5.24.
After this sale, the director directly beneficially owns 2,565,591 shares of Class A Common Stock. In addition, the director has indirect beneficial ownership through three trusts holding 918,680 shares, 7,928,570 shares, and 335,719 shares of Class A Common Stock, respectively.
Organogenesis Holdings Inc. reported Q3 2025 results showing stronger profitability. Total revenue was $150.864M (net product revenue $150.487M), up from $115.177M a year ago. Income from operations rose to $20.727M, and net income reached $21.567M, or $0.11 per diluted share. Advanced Wound Care drove the quarter with $141.451M, while Surgical & Sports Medicine contributed $9.036M.
Year to date, revenue was $338.562M versus $355.387M in 2024, with a net loss of $6.668M. Cash and cash equivalents were $63.745M and operating cash flow was an outflow of $49.729M for the nine months. Accounts receivable increased to $168.783M and inventories to $39.583M. The company recorded $0.603M of grant income tied to the Smithfield facility buildout and ended the quarter with deferred grant income on the balance sheet.
The revolving credit facility was reduced to $75M with updated covenants; there were no outstanding borrowings. Management flagged potential Medicare LCD changes effective January 1, 2026 that would limit coverage for several products. In clinical updates, a second Phase 3 ReNu knee OA trial did not meet its primary endpoint; an FDA meeting is scheduled for December 12, 2025 to discuss a BLA using combined data.
Organogenesis Holdings (ORGO) reported that it announced its fiscal third-quarter results for the period ended September 30, 2025, via a press release dated November 6, 2025. The company furnished the press release as Exhibit 99.1 to an 8-K.
The company stated that the press release is being furnished and is not deemed filed for purposes of Section 18 of the Exchange Act. For full details, readers are directed to the furnished Exhibit 99.1.
Organogenesis Holdings Inc. (ORGO) insider activity: A director and 10% owner reported Form 4 transactions. An affiliated trust purchased 251,001 shares of Class A common stock on 05/14/2025 at a weighted-average price of $3.0878 and 107,494 shares on 05/15/2025 at a weighted-average price of $2.9862. The same trust sold 4,156 shares on 06/09/2025 at a weighted-average price of $3.5003 and 18,620 shares on 06/10/2025 at a weighted-average price of $3.5583.
Following the reported transactions, holdings included 335,719 shares indirectly by the Glenn Nussdorf 10 Year Follow On Trust and 3,065,591 shares held directly. The filing notes that the sales on 06/09/2025 and 06/10/2025 were matchable with a 05/15/2025 purchase under Section 16(b), and the reporting person paid the issuer $13,285.24, comprising $12,971.78 in profit plus $313.46 in interest.
Organogenesis Holdings, Inc. filed a Form 8-K reporting a material event that includes a press release dated September 25, 2025 and referenced data from Phase 3 randomized controlled trials (ReNu) dated the same day. The filing indicates the press release and trial data are provided as part of the 8-K's disclosures and that the interactive cover page data are embedded in the Inline XBRL document. The filing is signed by Lori Freedman, Chief Administrative and Legal Officer.
The filing text supplied here contains no actual trial results, financial figures, forward-looking statements, or additional narrative about the ReNu data, and therefore does not disclose outcomes, metrics, or impacts on operations or finances.
Organogenesis Holdings, Inc. Schedule 13G shows First Light Asset Management, LLC and Mathew P. Arens report joint beneficial ownership of common stock. The Manager is reported to beneficially own 8,061,404 shares (representing 6.35% of the class) while Mr. Arens is reported to beneficially own 8,309,404 shares (6.55%), including 231,000 shares held directly with sole voting and dispositive power. The filing is made under Rule 13d-1(b) and includes a joint filing agreement.
Organogenesis Holdings Inc. reporting person Brian Grow, the company's Chief Commercial Officer, disclosed transactions on 08/11/2025 involving both stock-option exercise and share transactions. The filing shows the exercise of a stock option that resulted in 4,060 Class A common shares acquired at an exercise price of $2.47, and it states that 100% of the shares subject to the option are fully vested and exercisable.
The Form 4 also reports a transaction involving 2,173 Class A common shares at a reported price of $4.615. The filing lists beneficial ownership figures of 674,550 and 672,377 Class A common shares on the respective lines, indicating the reporting person continues to hold hundreds of thousands of shares following these transactions.